(Total Views: 378)
Posted On: 11/08/2019 12:25:12 PM
Post# of 154882
Re: generactor #10650
By Nader's own words the cost is around $50M.
The licensing deal is critical for many reasons:
1) We don't have the money to launch Leronlimab
2) We don't have in-house commercialization expertise
3) We don't have sales force (commercialization infrastructure)
4) Other companies are working on their own drugs, need to reach market before them and "impose" our drug.
BTW, you know for a fact that Syneos is the commercialization company (the one we are working-out the the deal with ?). It would make sense if this is the case.
The licensing deal is critical for many reasons:
1) We don't have the money to launch Leronlimab
2) We don't have in-house commercialization expertise
3) We don't have sales force (commercialization infrastructure)
4) Other companies are working on their own drugs, need to reach market before them and "impose" our drug.
BTW, you know for a fact that Syneos is the commercialization company (the one we are working-out the the deal with ?). It would make sense if this is the case.
(1)
(0)
